Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Meso crawled time : 00:00 save search
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
Published: 2024-03-13 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 1.23%
H: 0.08%
C: -1.21%
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
Published: 2024-03-10 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 16.28%
H: 27.6%
C: 6.4%
drug device approval food heart
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
Published: 2024-01-18 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 10.47%
H: 2.63%
C: 1.05%
revascor rare drug disease children food designation heart grants
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
Published: 2023-11-26 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 2.26%
H: 2.94%
C: 0.74%
rare drug disease treatment heart
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
Published: 2023-11-21 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 6.61%
H: 3.88%
C: 3.88%
blood trials network trial
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
Published: 2023-10-31 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: -9.68%
H: 8.93%
C: 8.93%
report
Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
Published: 2023-08-04 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: -63.91%
H: 14.58%
C: 13.89%
drug disease children license food application response
Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy
Published: 2023-02-16 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: -2.51%
H: 0.0%
C: -5.44%
research meeting therapy
FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back Pain
Published: 2023-02-08 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 4.07%
H: 0.0%
C: -7.59%
fda designation grants back therapy
Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)
Published: 2023-01-31 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 9.09%
H: 3.61%
C: -0.28%
fda disease children application license
Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022
Published: 2022-11-22 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 3.08%
H: 0.15%
C: -0.3%
financial
Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Published: 2022-11-22 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 3.08%
H: 0.15%
C: -0.3%
disease children
Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022
Published: 2022-10-30 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 1.04%
H: 0.0%
C: -0.34%
financial
Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD
Published: 2022-10-02 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 8.45%
H: 4.35%
C: -1.09%
fda response
Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022
Published: 2022-08-30 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 8.06%
H: 2.0%
C: 0.34%
year
Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn’s Colitis After Direct Injection of Remestemcel-L by Colonoscopy
Published: 2022-02-20 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
| Email alert
Add to watchlist
cel injection ulcerative colitis
Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia
Published: 2021-12-05 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 5.25%
H: 0.0%
C: 0.0%
treatment heart risk cardio diabetes cardiovascular test
Operational Highlights and Financial Results for the Period Ended September 30, 2021
Published: 2021-11-23 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
financial results results
Appendix 4C Quarterly Activity Report
Published: 2021-10-28 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: -0.5%
H: 1.51%
C: 1.17%
report
Operational Highlights and Financial Results for the Year Ended June 30, 2021
Published: 2021-08-30 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: -13.39%
H: 6.47%
C: 3.0%
financial results results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.